Jacob Vincent Micallef - 17 Mar 2026 Form 4 Insider Report for VOLITIONRX LTD (VNRX)

Reporting relationship: Chief Scientific Officer
Issuer ticker: VNRX
Reported as of: 17 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Mar 2026, 16:30:18 UTC
Prior SEC filing: 27 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Jacob Vincent Micallef

Key filing fact

Jacob Vincent Micallef filed Form 4 for VOLITIONRX LTD (VNRX) on 19 Mar 2026.

Key facts

This page summarizes Jacob Vincent Micallef's Form 4 filing for VOLITIONRX LTD (VNRX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 19 Mar 2026, 16:30.

Change

Previous filing in this sequence was filed on 27 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001651671 Primary reporting owner

Micallef Jacob Vincent

Relationship: Chief Scientific Officer
Address: 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON
Signature: /s/ Jacob Vincent Micallef
Signature date: 19 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VNRX transaction

Common Stock

Tax liability

Transaction value
Shares: -5,310
Change %: -0.92%
Price: $0.1900^*
Shares after: 572,179
Date: 17 Mar 2026
Ownership: Direct
Footnotes: F1

VNRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 55,000
Date: 17 Mar 2026
Ownership: By Spouse

VNRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 38,113
Date: 17 Mar 2026
Ownership: By Borlaug Limited
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 11,800 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction.

Footnote F2

The shares of common stock are held directly by Borlaug Limited. The reporting person is a controlling director of Borlaug Limited and has voting and dispositive control over the shares of common stock held by Borlaug Limited.